Corneal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The predisposing factors of Corneal Neovascularization include infections, trauma to the eye, chemical burns, immune system diseases, and certain other eye conditions, such as uveitis and glaucoma. Its symptoms are irritation in the eyes, dryness and pink eye or conjunctivitis, and light sensitivity.
The Corneal Neovascularization pipeline market research report provides comprehensive information on the therapeutics under development for Corneal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects.
Corneal Neovascularization Pipeline Products Market Segmentation by Targets
The key targets in the Corneal Neovascularization pipeline products market are Ribonucleoprotein PTB Binding 2, Epidermal Growth Factor Receptor, GTPase KRas, Insulin Receptor Substrate 1, Low Density Lipoprotein Receptor Related Protein 6, Placenta Growth Factor, Platelet Derived Growth Factor Receptor Beta, Signal Transducer And Activator Of Transcription 3, Vascular Endothelial Growth Factor), Vascular Endothelial Growth Factor A, and others.
Corneal Neovascularization Pipeline Products Market Analysis by Targets
For more target insights into the Corneal Neovascularization pipeline products market, download a free report sample
Corneal Neovascularization Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Corneal Neovascularization pipeline products market are Ribonucleoprotein PTB Binding 2 Activator, Epidermal Growth Factor Receptor Agonist, GTPase KRas Inhibitor, Insulin Receptor Substrate 1 Inhibitor, Low Density Lipoprotein Receptor Related Protein 6 Antagonist, Placenta Growth Factor Inhibitor, Platelet Derived Growth Factor Receptor Beta Inhibitor, Signal Transducer And Activator Of Transcription 3 Inhibitor, Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, and others.
Corneal Neovascularization Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Corneal Neovascularization pipeline products market, download a free report sample
Corneal Neovascularization Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Corneal Neovascularization pipeline products market are ophthalmic, intraocular, intravitreal, and topical.
Corneal Neovascularization Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Corneal Neovascularization pipeline products market, download a free report sample
Corneal Neovascularization Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Corneal Neovascularization pipeline products market are gene therapy, antisense oligonucleotide, fusion protein, monoclonal antibody, recombinant protein, and small molecule.
Corneal Neovascularization Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Corneal Neovascularization pipeline products market, download a free report sample
Competitive Landscape
The leading companies in the Corneal Neovascularization pipeline products market are Chengdu Kanghong Pharmaceuticals Group Co Ltd, FortuneRock (China) Ltd, Gene Signal International SA, Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd, Kiora Pharmaceuticals Inc, Singh Biotechnology LLC, and Wntgen LLC.
Corneal Neovascularization Pipeline Products Market Analysis by Companies
To know more about the leading companies in the Corneal Neovascularization pipeline products market, download a free report sample
Corneal Neovascularization Pipeline Products Market Report Overview
Key Targets | Ribonucleoprotein PTB Binding 2, Epidermal Growth Factor Receptor, GTPase KRas, Insulin Receptor Substrate 1, Low Density Lipoprotein Receptor Related Protein 6, Placenta Growth Factor, Platelet Derived Growth Factor Receptor Beta, Signal Transducer And Activator Of Transcription 3, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, and Others |
Key Mechanisms of Action | Ribonucleoprotein PTB Binding 2 Activator, Epidermal Growth Factor Receptor Agonist, GTPase KRas Inhibitor, Insulin Receptor Substrate 1 Inhibitor, Low Density Lipoprotein Receptor Related Protein 6 Antagonist, Placenta Growth Factor Inhibitor, Platelet Derived Growth Factor Receptor Beta Inhibitor, Signal Transducer And Activator Of Transcription 3 Inhibitor, Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, and Others |
Key Routes of Administration | Ophthalmic, Intraocular, Intravitreal, and Topical |
Key Molecule Type | Gene Therapy, Antisense Oligonucleotide, Fusion Protein, Monoclonal Antibody, Recombinant Protein, and Small Molecule |
Leading Companies | Chengdu Kanghong Pharmaceuticals Group Co Ltd, FortuneRock (China) Ltd, Gene Signal International SA, Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd, Kiora Pharmaceuticals Inc, Singh Biotechnology LLC, and Wntgen LLC |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
FortuneRock (China) Ltd
Gene Signal International SA
Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd
Kiora Pharmaceuticals Inc
Singh Biotechnology LLC
Wntgen LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Corneal Neovascularization products market?
The key targets in the Corneal Neovascularization pipeline products market are Ribonucleoprotein PTB Binding 2, Epidermal Growth Factor Receptor, GTPase KRas, Insulin Receptor Substrate 1, Low Density Lipoprotein Receptor Related Protein 6, Placenta Growth Factor, Platelet Derived Growth Factor Receptor Beta, Signal Transducer And Activator Of Transcription 3, Vascular Endothelial Growth Factor), Vascular Endothelial Growth Factor A, and others.
-
What are the key mechanisms of action in the Corneal Neovascularization pipeline products market?
The key mechanisms of action in the Corneal Neovascularization pipeline products market are Ribonucleoprotein PTB Binding 2 Activator, Epidermal Growth Factor Receptor Agonist, GTPase KRas Inhibitor, Insulin Receptor Substrate 1 Inhibitor, Low Density Lipoprotein Receptor Related Protein 6 Antagonist, Placenta Growth Factor Inhibitor, Platelet Derived Growth Factor Receptor Beta Inhibitor, Signal Transducer And Activator Of Transcription 3 Inhibitor, Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, and others.
-
What are the key routes of administration in the Corneal Neovascularization pipeline products market?
The key routes of administration in the Corneal Neovascularization pipeline products market are ophthalmic, intraocular, intravitreal, and topical.
-
What are the key molecule types in the Corneal Neovascularization pipeline products market?
The key molecule types in the Corneal Neovascularization pipeline products market are gene therapy, antisense oligonucleotide, fusion protein, monoclonal antibody, recombinant protein, and small molecule.
-
Which are the leading companies in the Corneal Neovascularization pipeline products market?
The leading companies in the Corneal Neovascularization pipeline products market are Chengdu Kanghong Pharmaceuticals Group Co Ltd, FortuneRock (China) Ltd, Gene Signal International SA, Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd, Kiora Pharmaceuticals Inc, Singh Biotechnology LLC, and Wntgen LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.